Impact of Specialty Pharmacy, Site of Care, and Practice Ownership on Physician Behavior Chemotherapy dominates treatment of both ovarian cancer and endometrial cancer, although Avastin, a…
Vaccines are used to confer protection against a host of bacterial and viral pathogens that cause infections associated with high mortality and/or morbidity. Implementation of vaccination programs…
U.S. Payer and Prescriber Perspectives on Clinical Pathways, Bundled Payments, and Accountable Care Organizations As the U.S. healthcare market faces an avalanche of expensive specialty drugs in…
A Survey of Medical Oncologists and Interviews with Payers in the EU5 Hepatocellular carcinoma (HCC), thyroid cancer, gastrointestinal stromal tumor (GIST), and neuroendocrine tumors (NETs) fall…
Bladder cancer is one of the ten most common cancers worldwide that can afflict both genders and is the 13th most common cause of death associated with cancer. A mixture of immunotherapy (BCG…
Pancreatic cancer (PaC) is one of the most aggressive and highly lethal solid malignancies, with a 5-year survival of only 5%. Treatment of PaC is largely dependent on tumor size and location…
TreatmentTrends®: Prostate Cancer Q2 2015 (US) is part of a series of reports that examine current trends in the management of localized to metastatic prostate cancer from the perspective of both…
Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative opportunity for drug developers. Most excitement…
Which Attributes, in the Eyes of Oncologists and Payers, Will Allow Emerging Therapies to Gain Traction in a Market Experiencing Generic Erosion? Drug development for advanced/metastatic, hormone-…
TreatmentTrends®: Breast Cancer Q2 2015 (US) in the first in a series of reports that examine current trends in the management of advanced/metastatic breast cancer from the perspective of medical…
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular signaling…
LaunchTrends: Ibrance (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…
How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market? Patients with advanced/metastatic colorectal cancer (mCRC) typically receive chemotherapy (…
A Survey of Oncologists and MCO Pharmacy and Medical Directors Targeted small-molecule agents have emerged as key treatment options for biomarker-defined non-small-cell lung cancer (NSCLC)…
In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…
